scanX
Laurus Labs
add_icon

Laurus Labs

1,012.45
+1.85
(0.18%)
Market Cap
54,657.78 Cr
PE Ratio
64.88
Volume
9,27,968.00
Day High - Low
1,024.55 - 1,006.10
52W High-Low
1,141.00 - 512.35
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
54,657.78 Cr
EPS
6.65
PE Ratio
64.88
PB Ratio
11.35
Book Value
91.11
EBITDA
1,130.40
Dividend Yield
0.12 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
7.70
Debt to Equity
0.62
Analyst Rating and Forecast
- By Refinitiv from14 analysts
SELL
Analysts have suggested that investors can sell this stock
Buy
Buy+35.71 %
+35.71 %
Hold
Hold+21.43 %
+21.43 %
Sell
Sell+42.86 %
+42.86 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Laurus Labs Block Trade Worth Rs. 59.97 CroresJan 27, 2026
Laurus Labs witnessed a significant NSE block trade worth Rs. 59.97 crores involving approximately 593,935 shares at Rs. 1009.70 per share, indicating substantial institutional activity.
positive
Laurus Labs Targets Growth, 60% Margins in FY26Jan 27, 2026
Laurus Labs aims for strong operational growth in FY26 while maintaining stable gross margins around 60% for the upcoming quarter and next financial year.
positive
High-PE Stocks Defy Market Correction with Strong FundamentalsJan 25, 2026
Laurus Labs, Jain Resource Recycling, and Syrma SGS Technology maintain elevated valuations despite market weakness, supported by robust growth strategies and improving margins across their respective sectors.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,700.50
#1 4,08,006.91
37.20
#1 54,729.00
9.71
#1 10,980
16.07
53.25
Divis Laboratories
6,149.50
1,63,249.90
66.07
9,712.00
18.67
2,191
-1.02
48.15
Torrent Pharmaceuticals
4,261.50
1,44,228.52
64.43
11,539.40
6.99
1,911
26.24
70.35
Cipla
1,356.40
1,09,566.17
23.71
28,409.50
7.12
5,291
-57.18
45.95
Dr Reddys Laboratories
1,269.40
1,05,947.98
19.16
33,741.20
16.73
5,725
-15.28
58.53
Lupin
2,221.50
1,01,477.85
21.52
22,909.50
13.74
3,306
#1 37.44
60.82
Zydus Life Science
910.45
91,612.57
#1 18.12
23,511.00
18.55
4,615
-0.32
52.96
Mankind Pharma
2,083.30
85,999.68
47.17
12,744.20
#1 20.90
2,007
7.65
45.43
Aurobindo Pharma
1,184.60
68,801.76
19.14
32,345.60
9.43
3,484
7.59
51.95
Alkem Laboratories
5,480.50
65,527.60
26.80
13,458.30
3.70
2,216
1.90
40.44

Automatic Screeners on ScanX

Community
Resistance 1 Breached
Growth Rate
Revenue Growth
11.09 %
Net Income Growth
110.70 %
Cash Flow Change
-9.62 %
ROE
88.26 %
ROCE
51.95 %
EBITDA Margin (Avg.)
26.61 %

Quarterly Financial Results

Quarterly Financials
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
412
525
519
483
486
545
489
565
542
599
531
637
555
714
732
841
981
1,144
1,295
1,417
1,284
1,206
1,034
1,426
1,541
1,577
1,546
1,383
1,185
1,226
1,197
1,458
1,197
1,228
1,425
1,779
1,580
1,680
1,784
Expenses
325
408
406
358
382
426
392
443
459
513
442
523
467
575
581
647
696
765
862
940
883
858
744
1,028
1,085
1,127
1,141
1,095
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
1,298
EBITDA
87
116
112
125
104
119
97
122
83
86
89
114
88
139
150
194
285
379
433
477
401
348
291
398
456
450
405
287
170
190
184
260
174
183
295
479
393
430
486
Operating Profit %
21 %
21 %
20 %
24 %
20 %
21 %
18 %
21 %
15 %
13 %
17 %
18 %
15 %
19 %
20 %
23 %
29 %
33 %
33 %
33 %
31 %
29 %
28 %
28 %
30 %
28 %
26 %
21 %
14 %
15 %
15 %
17 %
14 %
15 %
20 %
24 %
24 %
24 %
27 %
Depreciation
25
26
27
28
30
30
31
35
38
40
43
44
46
48
48
46
49
51
52
54
59
63
64
66
71
82
84
87
91
93
98
102
106
108
106
110
117
121
121
Interest
28
25
31
17
19
20
18
23
22
25
24
18
23
26
21
21
15
14
17
22
27
22
23
31
29
40
43
53
39
42
51
51
49
53
58
56
52
40
39
Profit Before Tax
35
66
54
81
55
70
49
64
23
22
23
53
19
66
82
127
222
314
364
401
316
263
204
302
356
328
278
147
41
54
35
107
19
23
131
312
224
270
327
Tax
9
18
9
9
16
21
14
19
6
6
5
9
4
9
8
17
50
72
91
104
74
59
49
70
104
95
75
42
14
17
11
32
6
3
38
80
63
75
75
Net Profit
26
48
45
71
39
49
35
45
17
16
18
43
15
57
74
110
172
242
273
297
242
204
155
232
252
233
203
105
27
37
23
75
13
20
93
233
162
195
252
EPS in ₹
3.73
5.18
4.50
6.75
3.68
4.61
3.29
4.26
1.56
1.53
1.67
4.07
1.42
1.06
1.38
2.06
3.21
4.53
5.09
5.53
4.50
3.76
2.87
4.29
4.68
4.33
3.78
1.90
0.46
0.69
0.43
1.40
0.23
0.37
1.71
4.34
3.02
3.61
4.67
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,894
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,653
3,409
3,890
4,123
Current Assets
865
1,003
1,140
1,248
1,463
1,812
3,075
3,345
3,462
3,835
4,332
Capital Work in Progress
110
70
143
163
110
67
362
813
551
423
458
Investments
0
7
3
3
3
3
3
31
50
124
233
Other Assets
983
1,126
1,277
1,369
1,589
1,953
3,215
3,472
3,651
3,950
4,521
Total Liabilities
1,894
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
Current Liabilities
805
884
1,121
1,307
1,424
1,692
2,457
2,681
2,432
3,112
3,540
Non Current Liabilities
365
483
202
227
349
288
693
928
1,180
1,159
1,193
Total Equity
724
857
1,330
1,483
1,558
1,770
2,601
3,359
4,049
4,116
4,603
Reserve & Surplus
642
774
1,225
1,371
1,447
1,658
2,490
3,244
3,930
4,003
4,365
Share Capital
82
82
106
106
106
107
107
108
108
108
108
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
24
-27
-10
1
0
-1
47
27
-30
93
-39
Investing Activities
-397
-312
-289
-384
-253
-221
-941
-915
-997
-822
-680
Operating Activities
-65
182
332
343
298
347
733
911
994
666
602
Financing Activities
486
103
-54
42
-45
-128
255
30
-27
250
39
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
27.45 %
27.30 %
27.30 %
27.27 %
27.27 %
27.27 %
27.27 %
27.20 %
27.20 %
27.20 %
27.20 %
27.19 %
27.19 %
27.18 %
27.18 %
27.62 %
27.62 %
27.59 %
27.59 %
27.49 %
FIIs
0.00 %
0.04 %
0.04 %
0.02 %
0.02 %
0.02 %
0.00 %
0.02 %
0.02 %
0.00 %
0.00 %
0.00 %
25.97 %
25.67 %
26.08 %
25.56 %
25.52 %
25.70 %
26.16 %
26.52 %
DIIs
2.06 %
2.40 %
2.11 %
2.77 %
3.51 %
4.77 %
8.98 %
9.51 %
9.74 %
10.14 %
10.71 %
10.77 %
11.77 %
13.56 %
13.05 %
12.74 %
11.77 %
11.94 %
11.73 %
12.43 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
34.17 %
34.18 %
32.91 %
32.87 %
31.15 %
28.42 %
27.96 %
28.95 %
28.49 %
28.26 %
26.49 %
25.01 %
23.95 %
22.68 %
22.67 %
22.72 %
23.65 %
23.12 %
23.33 %
22.64 %
Others
36.32 %
36.07 %
37.65 %
37.08 %
38.05 %
39.53 %
35.80 %
34.32 %
34.55 %
34.39 %
35.60 %
37.03 %
11.12 %
10.91 %
11.03 %
11.36 %
11.44 %
11.65 %
11.18 %
10.92 %
No of Share Holders
2,35,836
2,99,257
3,94,053
4,67,419
4,27,465
4,07,186
3,90,695
4,23,931
4,18,615
4,17,977
4,02,640
3,82,880
3,56,830
3,24,059
3,09,063
2,92,214
2,92,905
2,80,223
2,83,678
2,80,756

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 1.5 1.5 1.5 2.5 2 2 2 0.8 1.2 0.00
Dividend Yield (%) 1.49 1.88 2.31 0.69 0.34 0.67 0.51 0.13 0.12 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Feb 2021 DIVIDEND Dividend
₹ 0.40 /share
 08 Feb 2021 366.20 356.95
12 May 2021 DIVIDEND Dividend
₹ 0.80 /share
 11 May 2021 474.45 491.75
18 Nov 2021 DIVIDEND Dividend
₹ 0.80 /share
 17 Nov 2021 574.90 484.00
11 May 2022 DIVIDEND Dividend
₹ 1.20 /share
 10 May 2022 578.80 525.10
04 Nov 2022 DIVIDEND Dividend
₹ 0.80 /share
 03 Nov 2022 526.20 477.75
10 May 2023 DIVIDEND Dividend
₹ 1.20 /share
 10 May 2023 300.05 334.30
02 Nov 2023 DIVIDEND Dividend
₹ 0.40 /share
 02 Nov 2023 396.40 358.90
08 May 2024 DIVIDEND Dividend
₹ 0.40 /share
 08 May 2024 434.40 429.45
11 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 11 Jul 2024 434.40 472.50
24 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Oct 2024 480.30 449.35
06 Nov 2024 DIVIDEND Dividend
₹ 0.40 /share
 06 Nov 2024 449.35 489.25
24 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Jan 2025 611.75 585.15
24 Apr 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 24 Apr 2025 564.25 650.45
09 May 2025 DIVIDEND Dividend
₹ 0.80 /share
 09 May 2025 650.45 586.00
26 Jun 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 26 Jun 2025 606.00 669.75
25 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 25 Jul 2025 778.30 836.50
23 Oct 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Oct 2025 858.25 923.90
31 Oct 2025 DIVIDEND Dividend
₹ 0.80 /share
 31 Oct 2025 923.90 970.35
23 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 23 Jan 2026 1,100.90 1,004.95

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 28, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 23, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJan 23, 2026
Board Meeting Outcome for Outcome Of The Board MeetingJan 23, 2026
Results - Financial Results For Quarter Ended December 31 2025Jan 23, 2026
Intimation Of Grant Of Stock Options To The Eligible EmployeesJan 23, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 09, 2026
Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025Jan 09, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Closure of Trading WindowDec 29, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 23, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 12, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 01, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptOct 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeOct 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 23, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationOct 23, 2025
Corporate Action-Board approves DividendOct 23, 2025
Board Meeting Outcome for Approval Of Unaudited Financial Statements For The Quarter And Half Year Ended September 30 2025 And Approval For Payment Of Interim Dividend For FY 2025-26Oct 23, 2025
Financial Results For The Quarter And Half Year Ended September 30 2025Oct 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 09, 2025
Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 And The Proposal For Payment Of Interim Dividend For FY 2025-26Oct 09, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationSep 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Scheme Of Arrangement Under Regulation 37(6) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementAug 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 30, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 29, 2025
Allotment Of 531.77 Acres Of Land By The Government Of Andhra PradeshJul 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 25, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 25, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30 2025Jul 25, 2025
Unaudited Financial Results For The Quarter Ended 30.06.2025Jul 25, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 09, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended June 30 2025Jul 09, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Innovation Fund Direct-Growth
1.85%
-150000
-0.80%
-0.74%
Capitalmind Flexi Cap Fund Direct - Growth
0.00%
-49410
-1.76%
-1.68%
JioBlackRock Flexi Cap Fund Direct-Growth
0.56%
-19472
-0.20%
-0.23%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
2.83%
10000
0.00%
1.56%
The Wealth Company Arbitrage Fund Direct-Growth
0.40%
8500
0.40%
0.40%
Kotak Active Momentum Fund Direct-Growth
3.42%
-6031
-0.41%
0.26%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
1.97%
5212
-0.18%
-0.04%
TRUSTMF Multi Cap Fund Direct-Growth
1.03%
4371
-0.13%
0.02%
Quant Arbitrage Fund Direct - Growth
0.16%
4250
0.16%
0.16%
Franklin India Multi-Factor Fund Direct - Growth
0.65%
2943
-0.06%
0.65%
Samco Small Cap Fund Direct - Growth
0.18%
-1870
-0.17%
0.18%
Kotak Nifty Alpha 50 Index Fund Direct-Growth
3.18%
1227
-0.36%
-1.50%
Aditya Birla Sun Life BSE 500 Momentum 50 Index Fund Direct-Growth
2.57%
809
-0.29%
-0.97%
Kotak Nifty500 Momentum 50 Index Fund Direct-Growth
2.25%
234
-0.26%
2.25%
DSP Nifty 500 Index Fund Direct-Growth
0.19%
234
0.19%
0.19%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
1.96%
223
-0.17%
1.96%
DSP Nifty Healthcare Index Fund Direct-Growth
3.99%
178
-0.39%
0.01%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
2.77%
148
-0.29%
2.77%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.66%
40
-0.07%
0.66%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.18%
19
-0.02%
-0.01%
Kotak Arbitrage Fund Direct-Growth
0.48%
0
0.00%
0.19%
Mirae Asset Arbitrage Fund Direct - Growth
0.45%
0
0.00%
-0.13%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.19%
0
0.00%
-0.02%
Baroda BNP Paribas Arbitrage Fund Direct - Growth
0.23%
0
0.00%
-0.05%
Bandhan Nifty Alpha 50 Index Fund Direct-Growth
3.18%
0
0.00%
-0.36%

Technical Indicators

RSI(14)
Neutral
51.13
ATR(14)
Less Volatile
36.03
STOCH(9,6)
Neutral
68.87
STOCH RSI(14)
Overbought
97.72
MACD(12,26)
Bullish
6.32
ADX(14)
Weak Trend
20.22
UO(9)
Bearish
56.60
ROC(12)
Uptrend And Accelerating
3.83
WillR(14)
Overbought
-14.88
Bearish
4
Neutral
3
Bullish
2

About Laurus Labs

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs...more
Listing Date
19 Dec, 2016(9 Years, 29 days)
Website
https://www.lauruslabs.com
Chairperson NameRavindranath Kancherla
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104